BioSpace News Archive

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its pipeline of innovative vaccines with three new development programs based on the clinical success of its infectious disease vaccine portfolio to date.

Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) ― the world’s largest medical technology, services, and solutions company ― has received a new expanded indication from Health Canada for its Evolut™ Transcatheter Aortic Valve Implantation (TAVI) system.

On Track to Initiate Three Clinical Trials in 2021 Across Franchise of Targeted Hematology Therapies, Including Phase 3 Trial for SY-1425 in MDS

Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology company powering continuous delivery of approved drugs in novel indications, announced today that it has selected a subcutaneous lenalidomide formulation as the lead formulation candidate for its continuous subcutaneous delivery system (STAR-LLD SC) for chronic lymphocytic leukemia (CLL) and other hematologic malignancies.

The global preimplantation genetic testing market is projected to gain traction for analysing minor disabilities along with other serious ailments for instance cancer.

With technological advancements in the worldwide healthcare sector, there is remarkable growth in acceptance of blood collection tubes for liquid biopsy in a wide range of applications including research activities and vitro diagnostics.

Epilepsy is categorized as a chronic disease of the brain and continues to affect millions of individuals across the world

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that it anticipates reported and organic revenue growth of approximately 66% and 63%, respectively, GAAP earnings per share from continuing operations of at least $2.88, and adjusted earnings per share from continuing operations of at least $3.60 for the fourth quarter ended January 3, 2021.

Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, outlined significant clinical milestones for 2021 and provided an overview of recent progress.

AIM ImmunoTech Inc. and its CEO Thomas K. Equels announced that this week’s planned investor conference call will be postponed and rescheduled for a later date following the death of Mr. Equels’ mother over this past weekend.